Ablation of atrial fibrillation

Trends in Cardiovascular Medicine

Volumn 25, Issue 5, 2015, Pages 409-419

  Wright, Matthew ^a,b   Narayan, Sanjiv M ^c  

^a BHF Centre of Excellence   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULATION; ATRIAL FIBRILLATION; CATHETER ABLATION; HUMAN; MORTALITY; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TACHYCARDIA; TREATMENT INDICATION; PROCEDURES;

ANTICOAGULANT AGENT;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CATHETER ABLATION; HUMANS;

EID: 84930765706     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2014.11.009     Document Type: Review

References (111)

1. Chugh S.S., Havmoeller R., Narayanan K., Singh D., Rienstra M., Benjamin E.J., et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation 2014, 129:837-847.
2. Van Gelder I.C., Groenveld H.F., Crijns H.J., Tuininga Y.S., Tijssen J.G., Alings A.M., et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010, 362:1363-1373.
3. Roy D., Talajic M., Nattel S., Wyse D.G., Dorian P., Lee K.L., et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008, 358:2667-2677.
4. Saksena S., Slee A., Waldo A.L., Freemantle N., Reynolds M., Rosenberg Y., et al. Cardiovascular outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). An assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses. J Am Coll Cardiol 2011, 58:1975-1985.
5. Deshmukh A., Patel N.J., Pant S., Shah N., Chothani A., Mehta K., et al. In-hospital complications associated with catheter ablation of atrial fibrillation in the United States between 2000 and 2010: analysis of 93 801 procedures. Circulation 2013, 128:2104-2112.
6. Wilber D.J., Pappone C., Neuzil P., De Paola A., Marchlinski F., Natale A., et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. J Am Med Assoc 2010, 303:333-340.
7. Packer D.L., Kowal R.C., Wheelan K.R., Irwin J.M., Champagne J., Guerra P.G., et al. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. J Am Coll Cardiol 2013, 61:1713-1723.
8. Oral H., Pappone C., Chugh A., Good E., Bogun F., Pelosi F., et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med 2006, 354:934-941.
9. Van Brabandt H., Neyt M., Devos C. Caution over use of catheter ablation for atrial fibrillation. Br Med J 2013, 347:f5277.
10. Morillo C.A., Verma A., Connolly S.J., Kuck K.H., Nair G.M., Champagne J., et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. JAMA 2014, 311:692-700.
11. Nielsen J.C., Johannessen A., Raatikainen P., Hindricks G., Walfridsson H., Kongstad O., et al. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation. New Engl J Med 2012, 367:1587-1595.
12. Calkins C.H. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Heart Rhythm 2012, 9:632-696.
13. Parkash R., Tang A.S., Sapp J.L., Wells G. Approach to the catheter ablation technique of paroxysmal and persistent atrial fibrillation: a meta-analysis of the randomized controlled trials. J Cardiovasc Electrophysiol 2011, 22:729-738.
14. Swartz J.F., Pellersels S., Patten L., Cervantez D. A catheter-based curative approach to atrial fibrillation in humans. Circulation 1994, 90:335. [abstract].
15. Jais P., Haissaguerre M., Shah D.C., Chouairi S., Gencel L., Hocini M., et al. A focal source of atrial fibrillation treated by discrete radiofrequency ablation. Circulation 1997, 95:572.
16. Haissaguerre M., Jais P., Shah D.C., Takahashi A., Hocini M., Quiniou G., et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998, 339:659-666.
17. Ganesan A.N., Shipp N.J., Brooks A.G., Kuklik P., Lau D.H., Lim H.S., et al. Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis. J Am Heart Assoc 2013, 2:e004549.
18. McCready J.W., Smedley T., Lambiase P.D., Ahsan S.Y., Segal O.R., Rowland E., et al. Predictors of recurrence following radiofrequency ablation for persistent atrial fibrillation. Europace 2011, 13:355-361.
19. Verma A., Jiang Chen-Yang, Betts T., Chen J., Deisenhofer I., Mantovan R., et al. Optimal method and outcomes of catheter ablation of persistent AF: the STARAF 2 Trial. Eur Heart J 2014, [abstract].
20. Fuster V., Ryden L.E., Cannom D.S., Crijns H.J., Curtis A.B., Ellenbogen K.A., et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006, 114:e257-e354.
21. Hindricks G., Piorkowski C., Tanner H., Kobza R., Gerds-Li J.H., Carbucicchio C., et al. Perception of atrial fibrillation before and after radiofrequency catheter ablation: relevance of asymptomatic arrhythmia recurrence. Circulation 2005, 112:307-313.
22. Charitos E.I., Stierle U., Ziegler P.D., Baldewig M., Robinson D.R., Sievers H.H., et al. A comprehensive evaluation of rhythm monitoring strategies for the detection of atrial fibrillation recurrence: insights from 647 continuously monitored patients and implications for monitoring after therapeutic interventions. Circulation 2012, 126:806-814.
23. Jahangir A., Lee V., Friedman P.A., Trusty J., Hodge D., Kopecky S., et al. Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow-up study. Circulation 2007, 115:3050-3056.
24. Charitos E.I., Purerfellner H., Glotzer T.V., Ziegler P.D. Clinical classifications of atrial fibrillation poorly reflect its temporal persistence: insights from 1,195 patients continuously monitored with implantable devices. J Am Coll Cardiol 2014, 63:2840-2848.
25. January C.T., Wann L.S., Alpert J.S., Calkins H., Cleveland J.C., Cigarroa J.E., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014.
26. Morillo C.A., Verma A., Connolly S.J., Kuck K.H., Nair G.M., Champagne J., et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. J Am Med Assoc 2014, 311:692-700.
27. Healey J.S., Connolly S.J., Gold M.R., Israel C.W., Van Gelder I.C., Capucci A., et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012, 366:120-129.
28. Sanna T., Diener H.C., Passman R.S., Di Lazzaro V., Bernstein R.A., Morillo C.A., et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 2014, 370:2478-2486.
29. Daoud E.G., Glotzer T.V., Wyse D.G., Ezekowitz M.D., Hilker C., Koehler J., et al. Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: a subgroup analysis of TRENDS. Heart Rhythm 2011, 8:1416-1423.
30. Nattel S., Harada M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J Am Coll Cardiol 2014, 63:2335-2345.
31. Jackman W.M., Wang X.Z., Friday K.J., Roman C.A., Moulton K.P., Beckman K.J., et al. Catheter ablation of accessory atrioventricular pathways (Wolff-Parkinson-White syndrome) by radiofrequency current. N Engl J Med 1991, 324:1605-1611.
32. Jackman W.M., Beckman K.J., McClelland J.H., Wang X., Friday K.J., Roman C.A., et al. Treatment of supraventricular tachycardia due to atrioventricular nodal reentry by radiofrequency catheter ablation of slow-pathway conduction. N Engl J Med 1992, 327:313-318.
33. Weerasooriya R., Khairy P., Litalien J., Macle L., Hocini M., Sacher F., et al. Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up?. J Am Coll Cardiol 2011, 57:160-166.
34. Narayan S.M., Baykaner T., Clopton P., Schricker A., Lalani G., Krummen D.E., et al. Ablation of rotor and focal sources reduces late recurrence of atrial fibrillation compared to trigger ablation alone: extended followup of the CONFIRM (CONventional ablation with or without Focal Impulse and Rotor Modulation) Trial. J Am Coll Cardiol 2014, 63:1761-1768.
35. Joshi S., Choi A.D., Kamath G.S., Raiszadeh F., Marrero D., Badheka A., et al. Prevalence, predictors, and prognosis of atrial fibrillation early after pulmonary vein isolation: findings from 3 months of continuous automatic ECG loop recordings. J Cardiovasc Electrophysiol 2009, 20:1089-1094.
36. Abed H.S., Wittert G.A., Leong D.P., Shirazi M.G., Bahrami B., Middeldorp M.E., et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. J Am Med Assoc 2013, 310:2050-2060.
37. Pathak R.K., Middeldorp M.E., Lau D.H., Mehta A.B., Mahajan R., Twomey D., et al. Aggressive risk factor REduction STudy for Atrial Fibrillation (ARREST-AF Cohort Study): implications for the outcome of ablation. J Am Coll Cardiol 2014, [in press].
38. Weerasooriya R., Jais P., Hocini M., Scavee C., MacLe L., Hsu L.F., et al. Effect of catheter ablation on quality of life of patients with paroxysmal atrial fibrillation. Heart Rhythm 2005, 2:619-623.
39. Khaykin Y., Morillo C.A., Skanes A.C., McCracken A., Humphries K., Kerr C.R. Cost comparison of catheter ablation and medical therapy in atrial fibrillation. J Cardiovasc Electrophysiol 2007, 18:907-913.
40. Khaykin Y., Wang X., Natale A., Wazni O.M., Skanes A.C., Humphries K.H., et al. Cost comparison of ablation versus antiarrhythmic drugs as first-line therapy for atrial fibrillation: an economic evaluation of the RAAFT pilot study. J Cardiovasc Electrophysiol 2009, 20:7-12.
41. Wazni O.M., Marrouche N.F., Martin D.O., Verma A., Bhargava M., Saliba W., et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. J Am Med Assoc 2005, 293:2634-2640.
42. Naruse Y., Tada H., Satoh M., Yanagihara M., Tsuneoka H., Hirata Y., et al. Concomitant obstructive sleep apnea increases the recurrence of atrial fibrillation following radiofrequency catheter ablation of atrial fibrillation: clinical impact of continuous positive airway pressure therapy. Heart Rhythm 2013, 10:331-337.
43. Mohanty S., Mohanty P., Di Biase L., Bai R., Pump A., Santangeli P., et al. Impact of metabolic syndrome on procedural outcomes in patients with atrial fibrillation undergoing catheter ablation. J Am Coll Cardiol 2012, 59:1295-1301.
44. Marrouche N.F., Wilber D., Hindricks G., Jais P., Akoum N., Marchlinski F., et al. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. J Am Med Assoc 2014, 311:498-506.
45. Kapa S., Desjardins B., Callans D.J., Marchlinski F.E., Dixit S. Contact electroanatomic mapping derived voltage criteria for characterizing left atrial scar in patients undergoing ablation for atrial fibrillation. J Cardiovasc Electrophysiol 2014, 25:1044-1052.
46. Matsuo S., Lellouche N., Wright M., Bevalicqua M., Knecht S., Nault I., et al. Clinical predictors of termination and clinical outcome of catheter ablation for persistent atrial fibrillation. J Am Coll Cardiol 2009, 54:522-528.
47. Kornej J., Hindricks G., Kosiuk J., Arya A., Sommer P., Husser D., et al. Comparison of CHADS2, R2CHADS2, and CHA2DS2-VASc scores for the prediction of rhythm outcomes after catheter ablation of atrial fibrillation: the Leipzig Heart Center AF Ablation Registry. Circ Arrhythm Electrophysiol 2014, 7:281-287.
48. Schmitt C., Ndrepepa G., Weber S., Schmieder S., Weyerbrock S., Schneider M., et al. Biatrial multisite mapping of atrial premature complexes triggering onset of atrial fibrillation. Am J Cardiol 2002, 89:1381-1387.
49. Di Biase L., Burkhardt J.D., Mohanty P., Sanchez J., Mohanty S., Horton R., et al. Left atrial appendage: an underrecognized trigger site of atrial fibrillation. Circulation 2010, 122:109-118.
50. Elayi C.S., Di B.L., Bai R., Burkhardt J.D., Mohanty P., Sanchez J., et al. Identifying the relationship between the non-PV triggers and the critical CFAE sites post-PVAI to curtail the extent of atrial ablation in longstanding persistent AF. J Cardiovasc Electrophysiol 2011, 22:1199-1205.
51. Nattel S. New ideas about atrial fibrillation 50 years on. Nature 2002, 415:219-226.
52. Jiang R-H, Jiang C-Y, Sheng X., Zhang Z-W, Sun Y-X, Liu Q., et al. Marked suppression of pulmonary vein firing after circumferential pulmonary vein isolation in patients with paroxysmal atrial fibrillation: is pulmonary vein firing an epiphenomenon?. J Cardiovasc Electrophys 2014, 25:111-118.
53. Katritsis D.G., Pokushalov E., Romanov A., Giazitzoglou E., Siontis G.C., Po S.S., et al. Autonomic denervation added to pulmonary vein isolation for paroxysmal atrial fibrillation: a randomized clinical trial. J Am Coll Cardiol 2013, 62:2318-2325.
54. Dixit S., Marchlinski F.E., Lin D., Callans D.J., Bala R., Riley M.P., et al. Randomized ablation strategies for the treatment of persistent atrial fibrillation: RASTA study. Circ Arrhythm Electrophysiol 2012, 5:287-294.
55. Oral H., Chugh A., Good E., Igic P., Elmouchi D., Tschopp D.R., et al. Randomized comparison of encircling and nonencircling left atrial ablation for chronic atrial fibrillation. Heart Rhythm 2005, 2:1165-1172.
56. Pratola C., Baldo E., Notarstefano P., Toselli T., Ferrari R. Radiofrequency ablation of atrial fibrillation: is the persistence of all intraprocedural targets necessary for long-term maintenance of sinus rhythm?. Circulation 2008, 117:136-143.
57. Kuck K.H., Willems S., Breithardt G. GAP-AF Trial-AFNET1: (late breaking clinical trial abstract). Europace 2013.
58. Jiang R.H., Po S.S., Tung R., Liu Q., Sheng X., Zhang Z.W., et al. Incidence of pulmonary vein conduction recovery in patients without clinical recurrence after ablation of paroxysmal atrial fibrillation: mechanistic implications. Heart Rhythm 2014, 11:969-976.
59. Narayan S.M., Clopton P., Krummen D.E., Shivkumar K., Miller J. Direct or concidental ablation of localized sources may explain the success of atrial fibrillation ablation. On treatment analysis from the CONFIRM Trial. J Am Coll Cardiol 2013, 62:138-147.
60. O'Neill M.D., Wright M., Knecht S., Jais P., Hocini M., Takahashi Y., et al. Long-term follow-up of persistent atrial fibrillation ablation using termination as a procedural endpoint. Eur Heart J 2009, 30:1105-1112.
61. Oral H., Chugh A., Good E., Wimmer A., Dey S., Gadeela N., et al. Radiofrequency catheter ablation of chronic atrial fibrillation guided by complex electrograms. Circulation 2007, 115:2606-2612.
62. Oral H., Chugh A., Yoshida K., Sarrazin J.F., Kuhne M., Crawford T., et al. A randomized assessment of the incremental role of ablation of complex fractionated atrial electrograms after antral pulmonary vein isolation for long-lasting persistent atrial fibrillation. J Am Coll Cardiol 2009, 53:782-789.
63. Cochet H., Scherr D., Zellerhoff S., Sacher F., Derval N., Denis A., et al. Atrial structure and function 5 years after successful ablation for persistent atrial fibrillation: an MRI study. J Cardiovasc Electrophysiol 2014, 25:671-679.
64. Davidenko J.M., Pertsov A.V., Salomonsz R., Baxter W., Jalife J. Stationary and drifting spiral waves of excitation in isolated cardiac muscle. Nature 1992, 355:349-351.
65. Pandit S.V., Jalife J. Rotors and the dynamics of cardiac fibrillation. Circ Res 2013, 112:849-862.
66. Schuessler R.B., Grayson T.M., Bromberg B.I., Cox J.L., Boineau J.P. Cholinergically mediated tachyarrhythmias induced by a single extrastimulus in the isolated canine right atrium. Circ Res 1992, 71:1254-1267.
67. Moe G.K., Rheinboldt W.C., Abildskov J.A. A computer model of atrial fibrillation. Am Heart J 1964, 67:200-220.
68. Narayan S.M., Krummen D.E., Shivkumar K., Clopton P., Rappel W.J., Miller J. Treatment of atrial fibrillation by the ablation of localized sources: the conventional ablation for atrial fibrillation with or without focal impulse and rotor modulation: CONFIRM Trial. J Am Coll Cardiol 2012, 60:628-636.
69. Tzou W.S., Saghy L., Lin D. Termination of persistent atrial fibrillation during left atrial mapping. J Cardiovasc Electrophysiol 2011, 22:1171-1173.
70. Haissaguerre M., Hocini M., Shah A.J., Derval N., Sacher F., Jais P., et al. Noninvasive panoramic mapping of human atrial fibrillation mechanisms: a feasibility report. J Cardiovasc Electrophysiol 2013, 24:711-717.
71. Herweg B., Kowalski M., Steinberg J.S. Termination of persistent atrial fibrillation resistant to cardioversion by a single radiofrequency application. Pacing Clin Electrophysiol 2003, 26:1420-1423.
72. Narayan S.M., Shivkumar K., Mittal S., Briggs C.R., Sehra R., Miller J.M., et al. Conventional ablation for atrial fibrillation with or without focal impulse and rotor modulation: the CONFIRM Trial (Late Breaking Clinical Trial Abstract). Heart Rhythm 2011, 8. (LB-04).
73. Narayan S.M., Krummen D.E., Kahn A.M., Karasik P.L., Franz M.R. Evaluating fluctuations in human atrial fibrillatory cycle length using monophasic action potentials. Pacing Clin Electrophysiol 2006, 29:1209-1218.
74. Narayan S.M., Krummen D.E., Rappel W.J. Clinical mapping approach to diagnose electrical rotors and focal impulse sources for human atrial fibrillation. J Cardiovasc Electrophysiol 2012, 23:447-454.
75. Rappel W.J., Narayan S.M. Theoretical considerations for mapping activation in human cardiac fibrillation. Chaos 2013, 23:023113.
76. Narayan S.M., Bode F., Karasik P.L., Franz M.R. Alternans of atrial action potentials as a precursor of atrial fibrillation. Circulation 2002, 106:1968-1973.
77. Narayan S.M., Franz M.R., Clopton P., Pruvot E.J., Krummen D.E. Repolarization alternans reveals vulnerability to human atrial fibrillation. Circulation 2011, 123:2922-2930.
78. Lalani G., Schricker A., Gibson M., Rostamanian A., Krummen D.E., Narayan S.M. Atrial conduction slows immediately before the onset of human atrial fibrillation: a bi-atrial contact mapping study of transitions to atrial fibrillation. J Am Coll Cardiol 2012, 59:595-606.
79. Narayan S.M., Krummen D.E., Donsky A., Swarup V., Miller J.M. Precise rotor elimination without concomitant pulmonary vein isolation for the successful elimination of paroxysmal atrial fibrillation. PRECISE-PAF. Heart Rhythm 2013, 10:1414. [LBCT4].
80. Miller J.M., Kowal R.C., Swarup V., Daubert J.P., Daoud E.G., Day J.D., et al. Initial independent outcomes from focal impulse and rotor modulation ablation for atrial fibrillation: multicenter FIRM registry. J Cardiovasc Electrophys 2014, 25:921-929.
81. Kowal R.C., Daubert J., Day J., Ellenbogen K., Hummel J., Krummen D.E., et al. Results of focal impulse and rotor modulation (FIRM) for atrial fibrillation are equivalent between patients treated in San Diego compared with sites new to firm ablation: an extended multi-center experience. Heart Rhythm 2013, 10:S479. [abstract].
82. Lee G., Kumar S., Teh A., Madry A., Spence S., Larobina M., et al. Epicardial wave mapping in human long-lasting persistent atrial fibrillation: transient rotational circuits, complex wavefronts, and disorganized activity. Eur Heart J 2014, 35:86-97.
83. Ghoraani B., Dalvi R., Gizurarson S., Das M., Ha A., Suszko A., et al. Localized rotational activation in the left atrium during human atrial fibrillation: relationship to complex fractionated atrial electrograms and low-voltage zones. Heart Rhythm 2013, 10:1830-1838.
84. Haissaguerre M., Hocini M., Denis A., Shah A.J., Komatsu Y., Yamashita S., et al. Driver Domains in Persistent Atrial Fibrillation. Circulation 2014, 130:530-538.
85. Phan K., Xie A., La Meir M., Black D., Yan T.D. Surgical ablation for treatment of atrial fibrillation in cardiac surgery: a cumulative meta-analysis of randomised controlled trials. Heart 2014, 100:722-730.
86. Phan K., Xie A., Tian D.H., Shaikhrezai K., Yan T.D. Systematic review and meta-analysis of surgical ablation for atrial fibrillation during mitral valve surgery. Ann Cardiothorac Surg 2014, 3:3-14.
87. Packer D.L., Kowal R.C., Wheelan K.R., Irwin J.M., Champagne J., Guerra P.G., et al. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) Pivotal Trial. J Am Coll Cardiol 2013, 61:1713-1723.
88. Sediva L., Petru J., Skoda J., Janotka M., Chovanec M., Reddy V., et al. Visually guided laser ablation: a single-centre long-term experience. Europace 2014, 16:1746-1751.
89. Casado-Arroyo R., Chierchia G.B., Conte G., Levinstein M., Sieira J., Rodriguez-Manero M., et al. Phrenic nerve paralysis during cryoballoon ablation for atrial fibrillation: a comparison between the first- and second-generation balloon. Heart Rhythm 2013, 10:1318-1324.
90. Verma A., Debruyne P., Nardi S., Deneke T., DeGreef Y., Spitzer S., et al. Evaluation and reduction of asymptomatic cerebral embolism in ablation of atrial fibrillation, but high prevalence of chronic silent infarction: results of the evaluation of reduction of asymptomatic cerebral embolism trial. Circ Arrhythm Electrophysiol 2013, 6:835-842.
91. Kenigsberg D.N., Martin N., Lim H.W., Kowalski M., Ellenbogen K.A. Quantification of cryoablation zone demarcated by pre- and post-procedural electroanatomical mapping in atrial fibrillation patients using the 28mm second generation cryoballoon. Heart Rhythm 2014, in press.
92. Gersak B., Zembala M.O., Muller D., Folliguet T., Jan M., Kowalski O., et al. European experience of the convergent atrial fibrillation procedure: multicenter outcomes in consecutive patients. J Thorac Cardiovasc Surg 2014, 147:1411-1416.
93. Ferguson J.D., Helms A., Mangrum J.M., Mahapatra S., Mason P., Bilchick K., et al. Catheter ablation of atrial fibrillation without fluoroscopy using intracardiac echocardiography and electroanatomic mapping. Circ Arrhythm Electrophysiol 2009, 2:611-619.
94. Steven D., Servatius H., Rostock T., Hoffmann B., Drewitz I., Mullerleile K., et al. Reduced fluoroscopy during atrial fibrillation ablation: benefits of robotic guided navigation. J Cardiovasc Electrophysiol 2010, 21:6-12.
95. Sommer P., Richter S., Hindricks G., Rolf S. Non-fluoroscopic catheter visualization using MediGuide™ technology: experience from the first 600 procedures. J Interv Card Electrophysiol 2014, 40:209-214.
96. Wright M., Harks E., Deladi S., Suijver F., Barley M., van Dusschoten A., et al. Real-time lesion assessment using a novel combined ultrasound and radiofrequency ablation catheter. Heart Rhythm 2011, 8:304-312.
97. Natale A., Reddy V.Y., Monir G., Wilber D.J., Lindsay B.D., McElderry H.T., et al. Paroxysmal AF Catheter ablation with a contact force sensing catheter: results of the prospective, multicenter SMART-AF Trial. J Am Coll Cardiol 2014, 64:647-656.
98. Neuzil P., Reddy V.Y., Kautzner J., Petru J., Wichterle D., Shah D., et al. Electrical reconnection after pulmonary vein isolation is contingent on contact force during initial treatment: results from the EFFICAS I study. Circ Arrhythm Electrophysiol 2013, 6:327-333.
99. Piorkowski C., Eitel C., Rolf S., Bode K., Sommer P., Gaspar T., et al. Steerable versus nonsteerable sheath technology in atrial fibrillation ablation: a prospective, randomized study. Circ Arrhythm Electrophysiol 2011, 4:157-165.
100. Caponi D., Corleto A., Scaglione M., Blandino A., Biasco L., Cristoforetti Y., et al. Ablation of atrial fibrillation: does the addition of three-dimensional magnetic resonance imaging of the left atrium to electroanatomic mapping improve the clinical outcome?: a randomized comparison of Carto-Merge vs. Carto-XP three-dimensional mapping ablation in patients with paroxysmal and persistent atrial fibrillation. Europace 2010, 12:1098-1104.
101. January C.T., Wann L.S., Alpert J.S., Calkins H., Cigarroa J.E., Cleveland J.C. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. Executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014, 64:2246-2280.
102. Lip G.Y., Laroche C., Boriani G., Dan G.A., Santini M., Kalarus Z., et al. Regional differences in presentation and treatment of patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 2014.
103. Cappato R., Ezekowitz M.D., Klein A.L., Camm A.J., Ma C.S., Le Heuzey J.Y., et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014, in press.
104. Lakkireddy D., Reddy Y.M., Di Biase L., Vanga S.R., Santangeli P., Swarup V., et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol 2012, 59:1168-1174.
105. Macedo P.G., Kapa S., Mears J.A., Fratianni A., Asirvatham S.J. Correlative anatomy for the electrophysiologist: ablation for atrial fibrillation. Part I: pulmonary vein ostia, superior vena cava, vein of Marshall. J Cardiovasc Electrophysiol 2010, 21:721-730.
106. Macedo P.G., Kapa S., Mears J.A., Fratianni A., Asirvatham S.J. Correlative anatomy for the electrophysiologist: ablation for atrial fibrillation. Part II: regional anatomy of the atria and relevance to damage of adjacent structures during AF ablation. J Cardiovasc Electrophysiol 2010, 21:829-836.
107. Cappato R., Calkins H., Chen S.A., Davies W., Iesaka Y., Kalman J., et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation 2005, 111:1100-1105.
108. Cappato R., Calkins H., Chen S.A., Davies W., Iesaka Y., Kalman J., et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 2010, 3:32-38.
109. Hoyt H., Bhonsale A., Chilukuri K., Alhumaid F., Needleman M., Edwards D., et al. Complications arising from catheter ablation of atrial fibrillation: temporal trends and predictors. Heart Rhythm 2011, 8:1869-1874.
110. Bertaglia E., Stabile G., Pappone A., Themistoclakis S., Tondo C., Sanctis V.D., et al. Updated national multicenter registry on procedural safety of catheter ablation for atrial fibrillation. J Cardiovasc Electrophysiol 2013, 24:1069-1074.
111. Hoyt H., Nazarian S., Alhumaid F., Dalal D., Chilukuri K., Spragg D., et al. Demographic profile of patients undergoing catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2011, 22:994-998.